This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

SAP Depleter Dose Assessment Study in Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01406314
First received: July 26, 2011
Last updated: June 7, 2017
Last verified: June 2017
  Purpose
This study aims to provide safety information on the ligand, GSK2315698A. The pharmacokinetics and pharmacodynamics of the ligand will be determined together with the differences in routes of dose administration, namely the tolerability between intravenous versus subcutaneous dose administration. The study will be carried out in patients with systemic amyloidosis and the ability of GSK2315698A in depleting levels of serum amyloid protein (SAP) will be measured.

Condition Intervention Phase
Amyloidosis Drug: GSK2315698 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Other
Official Title: A Phase 1, Open Label, Dose Characteristic Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Intravenous and Subcutaneous Doses of GSK2315698A in Patients With Systemic Amyloidosis

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Blood concentrations of SAP [ Time Frame: 19 weeks ]
    comparison of predicted vs observed

  • Plasma concentrations of GSK2315698 [ Time Frame: 19 weeks ]
    changes in plasma concentrations of GSK2315698 over time


Secondary Outcome Measures:
  • safety and tolerability of GSK2315698 [ Time Frame: 19 weeks ]
    evaluated by adverse event (AE) reporting, clinical laboratory tests, vital signs, and 12-lead electrocardiogram (ECG).

  • Change from baseline in blood SAP levels [ Time Frame: 19 weeks ]
    evaluate effect of GSK2315698 on SAP levels in the blood


Enrollment: 17
Actual Study Start Date: October 13, 2011
Study Completion Date: November 14, 2012
Primary Completion Date: November 14, 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intervention
Intravenous infusion for approximately 48 hours followed by subcutaneous injection
Drug: GSK2315698
Intravenous infusion for approximately 48hours followed by subcutaneous injection

Detailed Description:
This study is an open label, dose characteristic study assessing safety and pharmacokinetic and pharmacodynamic considerations of GSK2315698A. GSK2315698A is a ligand known to bind to serum amyloid protein (SAP), a key component of an anti-SAP approach to the treatment of systemic amyloidosis. Safety assessments will include adverse events, vital signs, ECGs and other relevant clinical laboratory tests. Dose administration routes will also be determined focusing on the tolerability of intravenous dose administration versus subcutaneous. The study aims to recruit up to 30 patients with a medical diagnosis of systemic amyloidosis. Subjects will be asked to attend 2 dosing sessions, each session will involve an intravenous infusion of GSK2315698A over 48 hours followed by a single subcutaneous dose in session 1 and up to 3 subcutaneous doses in session 2 to be administered over a 24 hour period.
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • medically diagnosed with systemic amyloidosis
  • AST,ALT, alkaline phosphatase <= 3xULN and bilirubin ,1.5xULN
  • undergone radio-labelled-SAP scanning as part of their routine clinical care
  • male or female between 18 and 80 years of age inclusive, at time of signing the informed consent
  • subject is ambulant and capable of attending CUC
  • capable of giving written consent, which includes compliance with the requirements of the requirement and restrictions listed in the consent form
  • a female subjects is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea
  • male subjects with female partners of child-bearing potential must agree to use contraception methods listed in the protocol and informed consent information. This must be followed from the time of the first dose of study medication to 85 days post-last dose.
  • smokers (<10 cigarettes a day) are permitted but must be willing to abstain for the duration of residential study sessions

Exclusion Criteria:

  • a positive pre-study Hepatitis B surface antigen or Hepatitis C antibody result within 3 months of screening
  • the subject has participated in a clinical trial and has received an investigational therapeutic product (unlicensed) within 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
  • pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing
  • lactating females
  • unwillingness or inability to follow the procedures outlined in the protocol
  • subject is mentally or legally incapacitated
  • renal failure requiring haemodialysis will normally result in exclusion. Subjects in patient group 4 on haemodyalysis may be considered providing their schedule of dialysis can be accommodated within the study schedule
  • decompensated cardiac failure or recent history of syncope
  • clinically significant anaemia - Hb<9g/dL
  • use of prohibited medications
  • poor or unsuitable venous access
  • subjects with a QTc of > or equal to 480ms or other ECG abnormalities which, in the opinion of the investigator, is clinically significant in that they may increase safety risk
  • uncontrolled hypertension with systolic BP> 170mm Hg and/or diastolic >100 mm Hg
  • previous surgical procedures that result in altered anatomy of the upper digestive tract including cholecystectomy (gall bladder removal) will result in exclusion from the Entero-Test procedure, but the subject may still participate in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01406314

Locations
United Kingdom
GSK Investigational Site
Cambridge, United Kingdom, CB2 2GG
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Additional Information:
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01406314     History of Changes
Other Study ID Numbers: 114527
Study First Received: July 26, 2011
Last Updated: June 7, 2017

Keywords provided by GlaxoSmithKline:
Phase 1
Patient
Systemic Amyloidosis
Amyloidosis

Additional relevant MeSH terms:
Amyloidosis
Proteostasis Deficiencies
Metabolic Diseases

ClinicalTrials.gov processed this record on August 16, 2017